- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04790630
Cognitive Fitness for Depression in Older Adults
Cognitive Remediation of Cognitive Control in Late-Life Depression
Study Overview
Status
Intervention / Treatment
Detailed Description
Major depression in the elderly is both challenging to treat and detrimental to the cognitive functioning of patients. Major depression increases the probability of a later dementia diagnosis. By targeting cognitive processes in treatment, the investigators hope to both find a more effective means to manage major depression in older adults, but also demonstrate how top-down processes (e.g., Executive Control Network) may be driving depression and cognitive decline in older adults.
The investigators are recruiting older adults with and without mild cognitive impairment. All subjects must have at least mild depressive symptoms to be eligible to participate. Subjects will be randomly assigned to one of two different interventions.
Results of this study will help the investigators understand the mechanisms that contribute to depressed mood and cognitive change in older adults with late life depression.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Seyenah Lopez
- Phone Number: 860-679-6189
- Email: seylopez@uchc.edu
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- Recruiting
- UConn Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ability to read and write in English
- current major or mild depression despite ongoing treatment
- under the care of a physician who prescribes medication for depression
- currently treated with an antidepressant for at least 8 weeks
Exclusion Criteria:
- psychosis
- other psychiatric disorders (except personality & generalized anxiety disorders)
- substance use disorders in the prior year
- clinical diagnosis of dementia
- neurological disorders (e.g., stroke, epilepsy, brain injury with loss of consciousness > 30 minutes, brain tumors, demyelinating diseases)
- corrected visual acuity < 20/70 or color blindness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Computerized Cognitive Remediation of Executive Functioning (CCR-EF)
Initially 10 hours of processing speed exercises from "Brain HQ", (the 3 exercises are auditory tone sweep, visual processing [Double Decision], visual sweep). Following the 8-10 hours of Brain HQ, participants complete 8-10 hours of "Ultimate Word Master" before completing 16-20 hours of "Neurogrow" (formerly called "Catch the Ball"). Participants are asked to complete approximately 28-42 hours of computerized brain training over 4-6 weeks. |
computerized experimental brain-training treatment
|
ACTIVE_COMPARATOR: Active Control
Patients in the active control arm will complete three activities according to a standard protocol: 1) play a visuospatially oriented computer game (Myst), 2) watch computer-based educational programs on art, history, literature, and 3) play computer games online through the Brain HQ platform; games include crossword puzzles, soduko, paddleboard, and word search.
Participants will complete a total of 32-42 hours of training over 4-6 weeks.
Time spent on each task will be evenly divided (15 minutes of each task everday).
|
computerized intervention that follows recommendations for cognitive fitness
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in attention / cognitive flexibility as measured by the Trail Making Part B test
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
time to complete alpha-numeric sequencing
|
Pre-treatment and six weeks later when treatment has ended
|
Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
depression rating scale
|
Pre-treatment and six weeks later when treatment has ended
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in verbal learning as measured with the California Verbal Learning Test (CVLT) Total Learning
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
number of words recalled over 5 trials and spontaneous semantic organization of those words
|
Pre-treatment and six weeks later when treatment has ended
|
Change in attention processing speed as measured with the Flanker Test of Response Inhibition from the NIH Cognitive Toolbox
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
computerized test of response inhibition, speed of responding
|
Pre-treatment and six weeks later when treatment has ended
|
Change in self-reported depressive symptoms measured with the Carroll Depression Rating Scale
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
self-report of depression symptoms
|
Pre-treatment and six weeks later when treatment has ended
|
Change in problem solving/speed/spatial memory as measured with the NIH Toolbox fluid composite scales
Time Frame: Pre-treatment and six weeks later when treatment has ended
|
computerized picture memory, simple processing speed, problem solving/mental flexibility
|
Pre-treatment and six weeks later when treatment has ended
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kevin Manning, Ph.D., UConn Health
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-046-2
- 1K23MH118420-01A1 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Computerized Cognitive Remediation of Executive Functioning (CCR-EF)
-
VA Office of Research and DevelopmentCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Nathan Kline Institute for Psychiatric ResearchManhattan Psychiatric CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
University of Alabama at BirminghamRecruitingCognitive Impairment | Sickle Cell Disease | Self Efficacy | Coping Skills | Health-Related Behavior | Adolescent BehaviorUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownAttention Deficit Hyperactivity DisorderIsrael
-
University Hospital, CaenCompletedNeurodevelopmental Disorders | Child BehaviorFrance